The two patients with FGFR3-TACC3 rearrangements who received JNJ-42756493 manifested clinical improvement with stable disease and minor response, respectively.     ///    Three of 85 IDH1/2 wild-type (3.5%) but none of 126 IDH1/2-mutant grade II and III gliomas harbored FGFR3-TACC3 fusions.    ///    JNJ-42756493 inhibited growth of glioma cells harboring FGFR3-TACC3 in vitro and in vivo.     ///    FGFR3-TACC3 fusions were associated with strong and homogeneous FGFR3 immunostaining.     ///    FGFR3-TACC3 fusions are associated with uniform intratumor expression of the fusion protein.    ///    FGFR3-TACC3 fusions are associated with uniform intratumor expression of the fusion protein. 